The securities issued in the private placement are subject to a hold period of four months and one day from the date of issue. The private placement remains subject to the final approval of the Toronto Stock Exchange.
William J. Gastle, Microbix' Chief Executive Officer said, "The Company is approached from time to time by long term shareholders for direct investment which we try to accommodate based on our periodic need for working capital. We appreciate their show of support and confidence in the company".
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to a U.S. Person absent an exemption from the registration requirements.
Microbix Biosystems Inc. specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto. This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.
visit www.microbix.com or contact: William J. Gastle
CEO
Microbix Biosystems Inc.
(416) 234-1624 x 230; James Long
CFO
Microbix Biosystems Inc.
(416) 234-1624 x 265